Elevated cystatin C concentration and progression to pre-diabetes: The Western New York Study

Diabetes Care

Volumn 30, Issue 7, 2007, Pages 1724-1729

  Donahue, Richard P ^a   Stranges, Saverio ^a,b   Rejman, Karol ^a   Rafalson, Lisa B ^a   Dmochowski, Jacek ^a,c   Trevisan, Maurizio ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; CREATININE; CYSTATIN C; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERLEUKIN 6;

ADULT; AGED; ARTICLE; BODY MASS; CIGARETTE SMOKING; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; ETHNICITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION; HEALTH PROGRAM; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; INCIDENCE; INSULIN RESISTANCE; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREVALENCE; SENSITIVITY ANALYSIS;

AGED; CASE-CONTROL STUDIES; CYSTATINS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREDIABETIC STATE; PREDICTIVE VALUE OF TESTS;

EID: 34447128666     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-0040     Document Type: Article

References (45)

1. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
2. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M; Finnish Diabetes Prevention Study Group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
3. Narayan KM, Imperatore G, Benjamin SM, Engelgau MM: Targeting people with pre-diabetes. BMJ 325:403-404, 2002
4. Benjamin SM, Cadwell BL, Geiss LS, Engelgau MM, Vinicor F: A change in definition results in an increased number of adults with prediabetes in the United States. Arch Intern Med 164:2386, 2004
5. Donahue RP, Orchard TJ: Diabetes mellitus and macrovascular complications: an epidemiological perspective. Diabetes Care 15:1141-1155, 1992
6. Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects: Islington Diabetes Survey. Lancet 2:530-533, 1988
7. Kuusisto J, Mykkanen L, Pyorala K, Laakso M: Hyperinsulinemic microalbuminuria: a new risk indicator for coronary heart disease. Circulation 91:831-837, 1995
8. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 32:219-226, 1989
9. Klein R, Klein BE, Linton KL, Moss SE: Microalbuminuria in a population-based study of diabetes. Arch Intern Med 152:153-158, 1992
10. Mykkanen L, Zaccaro DJ, Wagenknecht LE, Robbins DC, Gabriel M, Haffner SM: Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the Insulin Resistance Atherosclerosis Study. Diabetes 47:793-800, 1998
11. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter LM: Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction - the Hoorn Study. Kidney Int Suppl 2004:S42-S44
12. Ochodnicky P, Vettoretti S, Henning RH, Buikema H, Van Dokkum RP, de Zeeuw D: Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. J Nephrol 19:246-258, 2006
13. Ritz E: Minor renal dysfunction: an emerging independent cardiovascular risk factor. Heart 89:963-964, 2003
14. Knowler WC, Narayan KM, Hanson RL, et al: Preventing non-insulin- dependent diabetes. Diabetes 44:483-488, 1995
15. Laterza OF, Price CP, Scott MG: Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48:699-707, 2002
16. Tan GD, Lewis AV, James TJ, Altmann P, Taylor RP, Levy JC: Clinical usefulness of cystatin C for the estimation of glomerular filtration rate in type 1 diabetes: reproducibility and accuracy compared with standard measures and iohexol clearance. Diabetes Care 25:2004-2009, 2002
17. Wattanakit K, Coresh J, Muntner P, Marsh J, Folsom AR: Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction. J Am Coll Cardiol 48:1183-1189, 2006
18. Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, Stehman-Breen C, Seliger SL, Kestenbaum B, Psaty B, Tracy RP, Siscovick DS: Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann Intern Med 145:237-246, 2006
19. O'Hare AM, Newman AB, Katz R, Fried LF, Stehman-Breen CO, Seliger SL, Siscovick DS, Shlipak MG: Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch Intern Med 165:2666-2670, 2005
20. Bibbins-Domingo K, Chertow GM, Fried LF, Odden MC, Newman AB, Kritchevsky SB, Harris TB, Satterfield S, Cummings SR, Shlipak MG: Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study. Arch Intern Med 166:1396-402, 2006
21. Randers E, Kristensen JH, Erlandsen EJ, Danielsen H: Serum cystatin C as a marker of the renal function. Scand J Clin Lab Invest 58:585-592, 1998
22. Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, Newman AB, Siscovick D, Shlipak MG; Cardiovascular Health Study: Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 142:497-505, 2005
23. Coll E, Botey A, Alvarez L, Poch E, Quinto L, Saurina A, Vera M, Piera C, Darnell A: Serum cystatin C as a new marker for non-invasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 36:29-34, 2000
24. Amann K, Wanner C, Ritz E: Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol 17:2112-2119, 2006
25. Donahue RP, Rejman K, Rafalson LB, Dmochowski J, Stranges S, Trevisan M: Sex differences in endothelial function markers before conversion to pre-diabetes: does the clock start ticking earlier among women? The Western New York Study. Diabetes Care 30:354-359, 2007
26. Stranges S, Trevisan M, Dorn JM, Dmochowski J, Donahue RP: Body fat distribution, liver enzymes, and risk of hypertension: evidence from the Western New York study. Hypertension 46:1186-1193, 2005
27. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560-2572, 2003
28. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
29. Bakker AJ: Detection of microalbuminuria: receiver operating characteristic curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care 22:307-313, 1999
30. Levey A, Greene T, Kusek J, Beck G: A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11 (Suppl.):55A, 2000
31. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470, 1999
32. Hankey GJ: Potential new risk factors for ischemic stroke: what is their potential? Stroke 37:2181-2188, 2006
33. Koenig W, Twardella D, Brenner H, Rothenbacher D: Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51:321-327, 2005
34. Microalbuminuria Collaborative Study Group UK: Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. Br Med J 306:1235-1239, 1993
35. Haffner SM, Stern MP, Gruber MK, Hazuda HP, Mitchell BD, Patterson JK: Microalbuminuria potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis 10:727-731, 1990
36. Groop L, Ekstrand A, Forsblom C, Widen E, Groop PH, Teppo AM, Eriksson J: Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 36:642-647, 1993
37. Shlipak MG, Praught ML, Sarnak MJ: Update on cystatin C: new insights into the importance of mild kidney dysfunction. Curr Opin Nephrol Hypertens 15:270-275, 2006
38. Shlipak MG, Fried LF, Crump C, et al: Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107(1):87-92, 2003
39. de Vegt F, Dekker JM, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study. Diabetes Care 21:1686-1690, 1998
40. Feskens EJ, Bowles CH, Kromhout D: Intra- and interindividual variability of glucose tolerance in an elderly population. J Clin Epidemiol 44:947-953, 1991
41. McDonald GW, Fisher GF, Burnham C: Reproducibility of the oral glucose tolerance test. Diabetes 14:473-480, 1965
42. Olefsky JM, Reaven GM: Insulin and glucose responses to identical oral glucose tolerance tests performed forty-eight hours apart. Diabetes 23:449-453, 1974
43. de Vegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpels G, Bouter LM, Heine RJ: Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn Study. JAMA 285:2109-2113, 2001
44. Costa A, Conget I, Gomis R: Impaired glucose tolerance: is there a case for pharmacologic intervention? Treat Endocrinol 1:205-210, 2002
45. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stahman-Breen C: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352:2049-2060, 2005